BioMarin to Presents Results of in P-I/II Study for the Treatment of Hemophilia A at ISTH 2022
Shots:
- The P-I/II study evaluates valoctocogene roxaparvovec in adults with sev. hemophilia A. Additionally, 6e13vg/kg & 4e13 vg/kg cohorts were followed for 6 & 5yrs. after treatment & valoctocogene roxaparvovec exhibited maintained hemostatic effectiveness
- At the time of the data cut, patients in the 6e13/4e13 vg/kg cohort remain off prophylactic Factor VIII treatment, mean cumulative ABR remains 1≤ & 0.7, 95% & 91% reduction in mean ABR, 96% & 93% reduction in mean annualized factor VIII usage from baseline @6 & 5yrs.
- The company is expected to resubmit a BLA for valoctocogene roxaparvovec to the US FDA at the end of Sept. The MAA is under EMA’s review with an expected CHMP opinion in mid-2022
Ref: BioMarin | Image: BioMarin
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
